Thomas Modine (Lille, France) talks to Cardiovascular News about the PARTNER 3 trial comparing low-risk patients who had a transcatheter aortic valve replacement (TAVR) compared with those who underwent surgical aortic valve replacement (SAVR).
The PARTNER 3 findings showed that TAVR reduced the mortality, stroke and rehospitalisation at 12 months for patients with low surgical risk compared with SAVR.
Modine notes that the “beauty of the results” is that they are “disruptive to our practice”. They also confirm that patients who have aortic stenosis will get “better outcomes getting TAVR that SAVR”.
Modine finally outlines his view that the current limitation with TAVR “is not clinical” but that it is “more administrative and regulatory”. He adds that the studies should be taken to the regulators who should be told that “we need you to approve this”.
Add comment